In vitro hematotoxicity testing in drug development: A review of past, present and future applications

Current Opinion in Drug Discovery and Development

Volumn 6, Issue 1, 2003, Pages 100-109

  Rich, Ivan N ^a  

^a HemoGenix LLC   (United States)

Author keywords

Chronotherapeutics; Chronotoxicology; Colony forming assays; Hematopoiesis; Hematotoxicity; High throughput assays; Stem cell

Indexed keywords

ANTINEOPLASTIC AGENT; BENZENE; BROXURIDINE; FLUOROURACIL; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROXYUREA; THYMIDINE; XENOBIOTIC AGENT;

ASSAY; BLOOD TOXICITY; BONE MARROW TOXICITY; CELL DIFFERENTIATION; CELL DIVISION; CELL LINEAGE; CELL POPULATION; CELL PROLIFERATION; CHEMOLUMINESCENCE; CHRONOBIOLOGY; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL RESEARCH; CLINICAL TRIAL; COLONY FORMING CELL; COLONY FORMING UNIT S; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST; DRUG DEVELOPMENT; EXPERT SYSTEM; GENOTOXICITY; HEMATOPOIESIS; HEMATOPOIETIC SYSTEM; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LYMPHOPOIESIS; MEGAKARYOCYTE; NONHUMAN; PARAMETER; PREDICTION; PUBLICATION; REPRODUCIBILITY; REVIEW; STANDARDIZATION; STEM CELL; STEM CELL TRANSPLANTATION; TARGET CELL; TECHNIQUE; TECHNOLOGY; TOXICITY TESTING; VALIDATION PROCESS;

ANIMALS; BLOOD PHYSIOLOGY; CIRCADIAN RHYTHM; COLONY-FORMING UNITS ASSAY; HEMATOLOGIC DISEASES; HEMATOPOIETIC SYSTEM; HUMANS; PHARMACEUTICAL PREPARATIONS; SPLEEN; STEM CELLS;

EID: 0037280022     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Bloom JC: Principles of hematotoxicology: Laboratory assessment and interpretation of data. Toxicol Pathol (1993) 21:130-134.
2. Parent-Massin D: Relevance of clonogenic assays in hematotoxicology. Cell Biol Toxicol (2001) 17:87-94. Discussion about the use of CFAs regarding toxicity testing. This paper is relevant in the context of reference [37].
3. Parchment RE, Gordon M, Grieshaber CK, Sessa C, Volpe D, Ghielmini M: Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Ann Oncol (1998) 9:357-364.
4. Parchment RE: Alternative testing systems for evaluating noncarcinogenic, hematologic toxicity. Environ Health Perspect (1998) 106(Suppl 2):541-557.
5. Rich IN: Primordial germ cells are capable of producing cells of the hematopoietic system in vitro. Blood (1995) 86:463-472.
6. Special issue on stem cell plasticity. Exp Hematol (2002) 30:847-972. A good introduction to the field of hematotoxicity testing.
7. Frisen J: Stem cell plasticity? Neuron (2002) 35:415-418.
8. Forbes SJ, Vig P, Poulsom R, Wright NA, Alison MR: Adult stem cell plasticity: New pathways of tissue regeneration become visible. Clin Sci (2002) 103:355-369.
9. Jensen G, Drapeau C: The use of in situ bone marrow stem cells for the treatment of various degenerative diseases. Med Hypotheses (2002) 59:422.
10. Kruger GM, Morrison SJ: Brain repair by endogenous progenitors. Cell (2002) 110:399-402.
11. Till JE, McCulloch EA: A direct measurement of the radiation sensitivity of normal bone marrow cells. Radiat Res (1961) 14:213-213. This paper launched modem experimental hematology and stem cell transplantation, by showing that some cells in hematopoietic tissue can repopulate in a lethally irradiated host.
12. Necas E, Ponka P, Neuwirt J: Changes in stem cell compartments in mice after hydroxyurea. Cell Tissue Kinet (1978) 11:119-127.
13. Hodgson GS, Bradley TR, Martin RF, Sumner M, Fry P: Recovery of proliferating haemopoietic progenitor cells after killing by hydroxyurea. Cell Tissue Kinet (1975) 8:51-60. One of the primary papers demonstrating that the stem cell compartment consists of a hierarchy of cells, and that stem cells can be synchronized.
14. Rosendaal M, Hodgson GS, Bradley TR: Haemopoletic stem cells are organised for use on the basis of their generation-age. Nature (1976) 264:68-69. A classic paper demonstrating that, when a single dose of 5-FU is administered to mice, all proliferating stem cells are killed, but surviving quiescent cells can reconstitute the animal.
15. Bradley TR, Metcalf D: The growth of mouse bone marrow cells in vitro. Aust J Exp Biol Med Sci (1966) 44:287-289. This paper and reference [16] showed that granulocyte-macrophage cells could form colonies in semi-solid medium in the presence of a factor contained in conditioned medium.
16. Pluznik DH, Sachs L: The induction of clones of normal mast cells by a substance from conditioned medium. Exp Cell Res (1966) 43:553-563. This study, performed independently from reference [15], demonstrated in vitro growth of hematopoietic colony-forming cells.
17. Cole RJ, Paul J: The effects of erythropoietin on haem synthesis in mouse yolk sac and cultured foetal liver cells. J Embryol Exp Morphol (1966) 15:245-260. This paper provided the impetus for Axelrad's team to develop a colony-forming assay for erythropoietic cells.
18. Stephenson JR, Axelrad AA, McLeod DL, Shreeve MM: Induction of colonies of hemoglobin-synthesizing cells by erythropoietin in vitro. Proc Natl Acad Sci USA (1971) 44:517-517. This is the first publication showing that erythropoietic cells can be grown as colonies. The cell population (CFU-E) is equivalent to the first morphologically identifiable erythroblast, the pronomoblast.
19. Axelrad AA, McLeod DL, Shreeve MM, Heath DS: Properties of cells that produce erythrocytic colonies in vitro. In: Hemopoiesis in Culture. Robinson W (Ed), US Government Printing Office, Washington DC, USA (1973):226-226. Discovery of the most primitive erythropoietic colony-forming cell.
20. Iscove NN, Sieber F, Winterhalter KH: Erythroid colony formation in cultures of mouse and human bone marrow; analysis of the requirement for erythropoietin by gel filtration and affinity chromatography on agarose-concanavalin A. J Cell Physiol (1974) 83:309-320. This is the first paper on the use of methyl cellulose to grow erythropoietic precursor cells.
21. Iscove NN, Sieber F: Erythroid progenitors in mouse bone marrow detected by macroscopic colony formation in culture. Exp Hematol (1975) 3:32-43. This study presents the growth of BFU-E in methyl cellulose.
22. Iscove NN, Guilbert LJ, Weyman C: Complete replacement of serum in primary cultures of erythropoietin-dependent red cell precursors (CFU-E) by albumin, transferrin, iron, unsaturated fatty acid, lecithin and cholesterol. Exp Cell Res (1980) 126:121-126. The serum-free conditions, or slight modifications thereof, described in this paper have been used for virtually every hematopoietic lineage.
23. Metcalf D: Hematopoietic Colonies: In vitro Cloning of Normal and Leukemic Cells. Springer-Verlag, New York, NY, USA (1977). Although over 20 years old, this is an excellent treatise on all aspects of hematopoietic cell cloning.
24. Dexter TM, Allen TD, Lajtha LG: Conditions controlling the proliferation of haemopoietic stem cells in vitro. J Cell Physiol (1977) 91:335-344. This article introduced the in vitro microenvironment and the most primitive in vitro stem cells.
25. Ploemacher RE, van der Sluijs JP, van Beurden CA, Baert MR, Chan PL. Use of limiting-dilution type long-term marrow cultures in frequency analysis of marrow-repopulating and spleen colony-forming hematopoietic stem cells in the mouse. Blood (1991) 78:2527-2533.
26. Ploemacher RE, van der Sluijs JP, Voerman JS, Brons NH: An in vitro limiting-dilution assay of long-term repopulating hematopoietic stem cells in the mouse. Blood (1989) 74:2755-2763. This paper quantified the most primitive murine in vitro stem cell population, the CAFC.
27. Sutherland HJ, Eaves CJ, Eaves AC, Dragowska W, Lansdorp PM: Characterization and partial purification of human marrow cells capable of initiating long-term hematopoiesis in vitro. Blood (1989) 74:1563-1570. This study introduced the human equivalent of the CAFC, called the LTC-IC.
28. Wendling F, Maraskovsky E, Debili N, Florindo C, Teepe M, Titeux M, Methia N, Breton-Gorius J, Cosman D, Vainchenker W: cMpl ligand is a humoral regulator of megakaryocytopoiesis. Nature (1994) 369:571-574.
29. Kaushansky K, Lok S, Holly RD, Broudy VC, Lin N, Bailey MC, Forstrom JW, Buddle MM, Oort PJ, Hagen FS et al. Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin. Nature (1994) 369:568-571.
30. Lok S, Kaushansky K, Holly RD, Kuijper JL Lofton-Day CE, Oort PJ, Grant FJ, Heipel MD, Burkhead SK, Kramer JM et al: Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo. Nature (1994) 369:565-568.
31. De Sauvage FJ, Hass PE, Spencer SD, Malloy BE, Gumey AL, Spencer SA, Darbonne WC, Henzel WJ, Wong SC, Kuang WJ et al. Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand. Nature (1994) 369:533-538.
32. Metcalf D: Blood. Thrombopoietin-at last. Nature (1994) 369:519-520.
33. Parchment RE, Huang M, Erickson-Miller CL: Roles for in vitro myelotoxicity tests in preclinical drug development and clinical trial planning. Toxicol Pathol (1993) 21:241-250.
34. Parchment RE, Gordon M, Grieshaber CK, Sessa C, Volpe D, Ghielmini M: Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Ann Oncol (1998) 9:357-364.
35. National Institutes of Health: Report of the International Workshop on In vitro Methods for Assessing Acute Systemic Toxicity. NIH Publication 01-4499 (2001). http://iccvam.niehs.nih.gov/methods/invidocs/finalrpt/finalcov.htm
36. Gribaldo L, Bueren J, Deldar A, Holdand P, Meredith C, Moneta D, Mosesso P, Parchment RE, Parent-Massin D, Pessina A, San Roman J, Schoeters G: The use of in vitro systems for evaluating haematotoxicity. The report and recommendations of ECVAM workshop 14. ATLA Lab Animals (1997) 24:211-231. An excellent introduction and description of available techniques for hematotoxicity testing with comments, criticisms and future trends.
37. Prieto P: ECVAM's in-house prevalidation/validation studies in the areas of haematotoxicity, reproductive toxicity, metabolism-mediated toxicity and epithelial barrier function. Sci Total Environ (2000) 247:349-354.
38. van Den Heuvel RL, Leppens H, Schoeters GE: Use of in vitro assays to assess hematotoxic effects of environmental compounds. Cell Biol Toxicol (2001) 17:107-116.
39. Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods (1983) 65:55-63.
40. Horowitz D, King AG: Colorimetric determination of inhibition of hematopoietic progenitor cells in soft agar. J Immunol Methods (2000) 244:49-58.
41. Bradbury DA, Simmons TD, Slater KJ, Crouch SP: Measurement of the ADP:ATP ratio in human leukaemic cell lines can be used as an indicator of cell viability, necrosis and apoptosis. J Immunol Methods (2000) 240:79-92.
42. Crouch SP, Kozlowski R, Slater KJ, Fletcher J: The use of ATP bioluminescence as a measure of cell proliferation and cytotoxicity. J Immunol Methods (1993) 160:81-88.
43. Bradbury DA, Simmons TD, Slater KJ, Crouch SPM: Measurement of the ADP:ATP ratio in human leukaemic cell lines can be used as an indicator of cell viability, necrosis and apoptosis. J Immunol Methods (2000) 240:79-92.
44. Musk P, Rich IN: A new high throughput stem cell and multilineage, progenitor cell assay for hemotoxicity testing. Toxicologist (2001) 66:LB139.
45. Rich IN, Musk P: HALO - A multifunctional colony-forming-based assay platform for drug development and basic and clinical research. Blood (2002) 100:618a.
46. HALO. HemoGenix LLC, Irmo, SC, USA. http://www.hemogenix.com
47. Levi F: From circadian rhythms to cancer chronotherapeutics. Chronobiol Int (2002) 19:1-19. This paper introduces a series of articles describing how circadian rhythms can be used in therapeutic applications.
48. Abrahamsen JF, Smaaland R, Sothem RB, Laerum OD: Circadian cell cycle variations of erythro- and myelopoiesis in humans. Eur J Haematol (1997) 58:333-345.
49. Bourin P, Ledain AF, Beau J, Mille D, Levi F: In vitro circadian rhythm of murine bone marrow progenitor production. Chronobiol Int (2002) 19:57-67.
50. Bertheault-Cvitkovic F, Jami A, Ithzald M, Brummer PD, Brienza S, Adam R, Kunstlinger F, Bismuth H, Misset JL, Levi F: Biweekly intensified ambulatory chronomodulated chemotherapy with oxaliplatin, fluorouracil, and leucovorin in patients with metastatic colorectal cancer. J Clin Oncol (1996) 14:2950-2958.
51. Hrushesky WJ, Dell I, Eaton J, Halberg F: Circardian-stage-dependent effect of doxorubicin upon reduced glutathione in the murine heart. Proc Am Assoc Cancer Res (1982) 23:12.